Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

y of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working to develop a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects the first microRNA diagnostic tests based on its technology to be launched during 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the development of therapeutics and diagnostic products, the progress and timing of our diagnostic and therapeutic programs, including the expected launch of the first diagnostic tests applying the Rosetta Genomics technology in 2008, and Rosetta's expected cash usage in 2008 constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the continued uncertainty in the credit and capital markets that may result in these markets deteriorating further or Rosetta experiencing additional ratings downgrades on any ongoing investments in its portfolio (including on ARS); changes in the accounting treatment and final results for 2007 resulting from final third party valuations of the ARS; the current lack of liquidity of the ARS having a impact on Rosetta's liquidity, cash flow or its ability to fund its operations; other changes in general economic and business conditions; Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products or services; Rosetta's ability to fun
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 Whitehouse Laboratories is ... term partnership with PTI Inspection Systems that ... state of the art leak testing method development and ... instruments currently available. As part of this agreement, Whitehouse ... Voltage Leak Detection Instrument developed and manufactured by ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
(Date:8/27/2014)... August 27, 2014 In 2013, ... Lawrence Livermore National Security LLC (LLNS), ... and deliver a state-of-the-art laser system for the ... Beamlines), under construction in the Czech Republic. , ... laser system, called the " High repetition-rate Advanced ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... Driven by the human genome project, and research in the ... antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents ... towards proteomics from genomics in the post-genome-project research period is ... years. , ...
... Nov. 12 Melbourne-based Starfish,Ventures announced today the ... $185 million, the largest venture capital fundraising in,Australia. ... and Cleantech,companies., The success of this fundraising ... of Australia,s ability to foster the development of,innovative ...
... Nov. 12 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) ... Graham as the Company,s Chief Executive Officer and as ... had been serving as,the Company,s acting Chief Executive Officer ... impressive job as acting CEO in managing the transition,of ...
Cached Biology Technology:World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 2World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 3Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors 2TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors 3
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
(Date:8/28/2014)... 28, 2014A new method for measuring and imaging how ... and researchers better understand how drug abuse affects the ... tissue engineering, and lead to better treatment options for ... team of researchers from Stony Brook University in New ... was published today in The Optical Society,s (OSA) open-access ...
(Date:8/28/2014)... significant health risk to people with asthma according to a ... Clinical Immunology . , By critically reviewing the findings from ... that the presence of several types of mould can lead ... the likelihood of developing the condition. , The research has ... Medical School and is the first time all of the ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... Missouri-Columbia has discovered a way to create engineered minichromosomes ... discovery opens new possibilities for the development of crops ... and herbicides, and for the development of proteins and ... , In a paper published in the Proceedings of ...
... In the daunting marathon that leads to successful ... before entering clinical trials. Researchers from Massachusetts Institute ... cell culture test for assessing a compound's genetic ... animal tests. This assay would allow genetic toxicity ...
... to rapid genetic adaptations in the nematode Acrobeloides ... and lay more eggs under polluted conditions than ... Doroszuk demonstrated this in her study into the ... , Environmental pollution is an important cause ...
Cached Biology News:Researchers attach genes to minichromosomes in maize 2DNA-damage test could aid drug development 2DNA-damage test could aid drug development 3Asexual worm quickly adapts to soil contamination 2
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... available in two product models - the 5000AT+ ... is that the 6000AT+ includes a membrane desolvation ... for improved detection limits and reduced oxides. The ... of elements by 10-40 times. Note that with ...
Biology Products: